#Sweden #Stockholm #Sobi #Haematology #ASH 2025

Sobi's Commitment to Haematology at ASH 2025

Sobi, the Swedish biopharma company known for its focus on breakthrough innovations in rare diseases, is set to participate in the 65th annual meeting of the American Society of Hematology (ASH 2025) from December 6 to 9 in Orlando, Florida. This event marks a significant gathering in the field of haematology, providing a platform for researchers, clinicians, and industry representatives to discuss advancements in the understanding and treatment of blood disorders.

At this year's conference, Sobi will present 19 scientific abstracts, including two crucial oral presentations, which showcase the latest clinical data from its innovative portfolio focused on treating rare and severe blood disorders. The findings include insights from various studies involving key Sobi therapeutic products such as efanesoctocog alfa, pegcetacoplan, avatrombopag, emapalumab, and pacritinib. This participation underscores Sobi's ongoing mission to enhance the quality of life for patients dealing with these serious health conditions.

Dr. Lydia Abad-Franch, MD, who is the Head of Research and Development and Chief Medical Officer at Sobi, emphasized the importance of new findings that will be presented at ASH. For example, data from a post hoc analysis on pacritinib demonstrates its effectiveness in reducing or stabilizing spleen size, improving haematologic parameters, and alleviating symptoms of myelofibrosis in patients with high-risk disease. The implications of these results are significant—they address critical factors that influence the quality of life for patients suffering from myelofibrosis, a debilitating blood cancer.

Sobi's presentations will cover a variety of topics related to haematology, including:

• - Innovative Treatments for Paroxysmal Nocturnal Haemoglobinuria (PNH): An overview of treatment progress using complement inhibitors, highlighting the efficacy of pegcetacoplan through case reports and user experiences.
• - Efanesoctocog Alfa Developments: Sharing clinical outcomes from long-term studies involving this treatment for severe Haemophilia A, revealing the impact on patient quality of life and treatment adherence.
• - Insights on Emapalumab: An investigation into its rapid effects in primary hemophagocytic lymphohistiocytosis (HLH) patients, showcasing beneficial outcomes that could lead to improved management strategies.
• - Pacritinib's Role in Myelofibrosis Management: Presentations will detail real-world treatment patterns and outcomes, emphasizing the need for adaptive treatment strategies in high-risk patients.

These sessions not only promote Sobi's advancements in treatment strategies but also foster discussions around unmet needs within haematology. The data provided at ASH will offer fellow researchers, healthcare professionals, and industry stakeholders invaluable insights into the current landscape of haematological treatments and the ongoing evolution brought about by innovative therapies.

Sobi’s commitment to providing life-altering treatments for patients with rare and severe blood disorders extends beyond their current portfolio. The collaboration with leading researchers and institutions enables Sobi to stay at the forefront of haematology research. As they showcase their latest findings, they continue to engage in discussions about improving patient outcomes and shaping the future of haematology.

The ASH meeting serves as an excellent opportunity for Sobi to not only display its research achievements but also connect with other experts in the field. The exchange of knowledge and advancements at such gatherings accelerates the path towards enhanced treatment options for patients in desperate need of effective therapies.

In conclusion, Sobi's participation at ASH 2025 reaffirms its dedication to pushing the boundaries of science and innovation in haematology. Patients suffering from blood disorders can look forward to transformative therapies that offer hope and improved quality of life as a result of the ongoing research and development efforts that the company champions.